Clinical Trial Update: Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of SN2310 Injectable Emulsion in patients with advanced solid tumors has completed, focusing on safety and dosing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Gynecologic Cancer
• Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• SN2310 Injectable Emulsion (SN2310)

Snippet

Sponsor: Achieve Life Sciences | Conditions: Breast Neoplasms, Colorectal Neoplasms | Phase 1 | Status: COMPLETED